From the CDC: Myocarditis and pericarditis after COVID-19 vaccination are rare. As of July 30, 2021, VAERS has received 1,249 reports of myocarditis or pericarditis among people ages 30 and younger who received COVID-19 vaccine. Most cases have been reported after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna), particularly in male adolescents and young adults. Through follow-up, including medical record reviews, CDC and FDA have confirmed 716 reports of myocarditis or pericarditis. CDC and its partners are investigating these reports to assess whether there is a relationship to COVID-19 vaccination
There were 716 confirmed reports. Most clustered in a population of 18-25 year old males. There are about 9 million fully vaccinated 18-25 year old males. For that demographic the chance of getting this side effect is about 1 in 15,000 which is greater than 1 in 20000, the chance of an equally serious side effect that got Rotashield pulled from the market in 1999.
From the CDC: Myocarditis and pericarditis after COVID-19 vaccination are rare. As of July 30, 2021, VAERS has received 1,249 reports of myocarditis or pericarditis among people ages 30 and younger who received COVID-19 vaccine. Most cases have been reported after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna), particularly in male adolescents and young adults. Through follow-up, including medical record reviews, CDC and FDA have confirmed 716 reports of myocarditis or pericarditis. CDC and its partners are investigating these reports to assess whether there is a relationship to COVID-19 vaccination
There were 716 confirmed reports. Most clustered in a population of 18-25 year old males. There are about 9 million fully vaccinated 18-25 year old males. For that demographic the chance of getting this side effect is about 1 in 15,000 which is greater than 1 in 20000, the chance of an equally serious side effect that got Rotashield pulled from the market in 1999.
Thank you, that puts the risks into perspective. Esp. the comparison to Rotashield.